This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
The historical rank and industry rank for Tandem Diabetes Care's Median PS Value or its related term are showing as below:
TNDM'
s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.39 Med: 0.57 Max: 0.64
Current: 0.39
During the past 13 years, the highest Price to Median PS Value of Tandem Diabetes Care was 0.64. The lowest was 0.39. And the median was 0.57.
TNDM's Price-to-Median-PS-Value is ranked better than 79.86% of 278
companies
in the Medical Devices & Instruments industry
Industry Median: 0.8
vs TNDM: 0.39
Tandem Diabetes Care Median PS Value Historical Data
The historical data trend for Tandem Diabetes Care's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Tandem Diabetes Care's Median PS Value
For the Medical Devices subindustry, Tandem Diabetes Care's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tandem Diabetes Care's Price-to-Median-PS-Value Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Tandem Diabetes Care's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Tandem Diabetes Care's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 3.9117.
Tandem Diabetes Care's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $14.357.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tandem Diabetes Care (NAS:TNDM) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Tandem Diabetes Care's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
22.14
/
56.16
=
0.39
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tandem Diabetes Care Median PS Value Related Terms
Thank you for viewing the detailed overview of Tandem Diabetes Care's Median PS Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for diabetes patients. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on a tubeless pump. Nearly three-quarters of total revenue is derived from the us, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one third is from disposable infusion sets that need to be changed over every 2 to 3 days.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
TNDM has been successfully added to your 